Format

Send to

Choose Destination
Int J Radiat Oncol Biol Phys. 2017 Aug 1;98(5):996-1001. doi: 10.1016/j.ijrobp.2017.03.018. Epub 2017 Mar 18.

Clinical Utility of Epstein-Barr Virus DNA Testing in the Treatment of Nasopharyngeal Carcinoma Patients.

Author information

1
Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. Electronic address: kimke@mail.nih.gov.
2
Department of Radiation Oncology, Stanford University School of Medicine, California.
3
Department of Radiation Oncology, University of California, San Francisco, California.
4
Department of Otolaryngology-Head and Neck Surgery, University of Toronto, Toronto, Ontario, Canada.
5
Department of Chemical Pathology, The Chinese University of Hong Kong, Hong Kong SAR, China.
6
Department of Radiation Oncology, Princess Margaret Cancer Centre/University of Toronto, Toronto, Ontario, Canada.
7
Center for Global Health, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
8
Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
9
Coordinating Center for Clinical Trials, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
10
Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

Abstract

Epstein-Barr virus (EBV) DNA analysis has been shown to be useful for early detection, prognostication, and monitoring of treatment response of nasopharyngeal carcinoma (NPC), and the recent literature provides growing evidence of the clinical utility of EBV DNA testing, particularly to inform treatment decisions for NPC patients. Despite the fact that NPC is a rare disease, the NRG Oncology cooperative group has successfully activated a phase 2/3 randomized clinical trial for NPC with international partners and in that process has discovered that the development of a harmonized EBV DNA test is absolutely critical for integration into clinical trials and for future deployment in clinical and central laboratories. In November 2015, the National Cancer Institute (NCI) convened a workshop of international experts in the treatment of NPC and EBV testing to provide a forum for discussing the state of EBV DNA testing and its clinical utility, and to stimulate consideration of future studies and clinical practice guidelines for EBV DNA. This review provides a summary of that discussion.

Comment in

PMID:
28721913
DOI:
10.1016/j.ijrobp.2017.03.018
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center